Cell and Gene Therapy Catapult

Activities: Cell & Gene Therapy

Trending Articles

  1. Lonza expands strategic collaboration with leading US biopharmaceutical company The tailor-made comprehensive offering spans a diversified clinical and commercial portfolio of innovative modalities, including process intensification and drug product...
  2. How a manufacturer tripled granulation line productivity A global manufacturer exporting to US markets was facing a 20% rejection rate for Sucralfate Tablets, leading to order non-fulfilment penalties
  3. Lonza expands HPAPI capacity in Visp to boost its position in payload-linker manufacturing Investment supports Lonza’s position in the ADC space by further developing its integrated ADC offering and expanding commercial-scale supply of highly potent payload-linker...
  4. The 7 most common process development mistakes At laboratory scale, processes may appear predictable, repeatable, and well understood. However this perceived level of control can be misleading
  5. Sanofi expands vaccine manufacturing in Abu Dhabi as NICE backs its diabetes therapy Sanofi advances on two fronts: a new Abu Dhabi vaccine innovation centre with AI and mRNA capabilities and UK NICE backing for teplizumab, the first disease-modifying treatment...

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

Related Content

Finance
Horiba joins cell & gene therapy manufacturing consortium

Horiba joins cell & gene therapy manufacturing consortium

Headed by the Cell and Gene Therapy Catapult, the consortium comprises technology providers, pharmaceutical companies, therapy developers and charities
Regulatory
NHC named National Training Centre for UK skills initiative

NHC named National Training Centre for UK skills initiative

The National Horizons Centre will provide hands-on training for advanced therapy medicinal products (ATMPs) and vaccine manufacture
Finance
Stevenage cell and gene therapy facility receives £3m government grant

Stevenage cell and gene therapy facility receives £3m government grant

The cell and gene therapy cluster around Stevenage has reportedly been recognised as a high potential opportunity zone, set to attract overseas investment to the
Regulatory
CGT Catapult analyses manufacturing and skills in cell and gene therapy

CGT Catapult analyses manufacturing and skills in cell and gene therapy

New data has shown cell and gene therapy manufacturing facilities are rapidly becoming operational reflecting job expansion in the sector
Media
British cell and gene therapy accelerator releases annual report

British cell and gene therapy accelerator releases annual report

The CGT Catapult has worked on more than 110 projects addressing industry challenges
Research & Development
CGT Catapult brings SMEs together

CGT Catapult brings SMEs together

Fujifilm Diosynth, Eversheds Sutherland, Mathys & Squire and Stifel gather at CGT Catapult’s first UK Advanced Therapy Medicinal Products Investor Day
Research & Development
TCR2 Therapeutics and CGT Catapult join forces at UK Bioscience park

TCR2 Therapeutics and CGT Catapult join forces at UK Bioscience park

TCR<sup>2</sup> is the first US company to have a global development base at the Stevenage site, working with CGT Catapult to further its T cell therapies
Subscribe now